JCR Pharmaceuticals Co Ltd 2025 Integrated Report
The report covers FY2024 operating and sustainability performance, highlighting a difficult financial year, the expansion of sustainability governance and materiality processes, and detailed Scope 1-3 emissions disclosure. It reports net sales of 33,072 million yen and 987 consolidated employees at March 31, 2025. The company also reports that Scope 3 represented about 80% of total GHG emissions and that Category 1 was the largest reported category.
Company: JCR Pharmaceuticals Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2025
Type: Integrated Report
Pages: 38
Back to company
JCR Pharmaceuticals Co Ltd
Integrated Report
The report covers FY2024 operating and sustainability performance, highlighting a difficult financial year, the expansion of sustainability governance and materiality processes, and detailed Scope 1-3 emissions disclosure. It reports net sales of 33,072 million yen and 987 consolidated employees at March 31, 2025. The company also reports that Scope 3 represented about 80% of total GHG emissions and that Category 1 was the largest reported category.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women in Management
Employees